Evernorth, the health services division of Cigna (CI), announced yesterday a pharmacy benefit offering that make weight loss medications Wegovy and Zepbound more available to patients. Through direct negotiations with the manufacturers, Evernorth has ensured that patients’ monthly cost will not exceed $200, the company said in a statement. Evernorth’s monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient’s annual deductible, it added. Shares of Hims & Hers (HIMS) are down 10% to $52.12 following the news from Evernorth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Hims & Hers falls after Cigna offers cheaper obesity drug plan
- Revised tax bill would speed up cuts to Medicaid, Bloomberg reports
- CMS to recover ‘uncollected overpayments’ amid Medicare audits
- CMS announces ‘significant expansion’ of Medicare Advantage audits
- Cigna Reaffirms 2025 Earnings Projection Amid Investor Meetings